Texas Heart Institute & 7 Hills Pharma awarded NIH grant to improve stem cell transplants
(Texas Heart Institute) The Texas Heart Institute and 7 Hills Pharma (7 Hills) received a $1.9 million, Phase II STTR (R42) grant from the National Heart Lung Blood Institute to advance further their lead product 7HP349, a novel integrin activator, to define the optimal dosing schedule for cord blood transplant along with a focus on development and production of a formulation that meets safety standards for filing an IND application with the FDA.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Cardiology | Grants | Heart | Heart Transplant | Lung Transplant | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants